Browsing Tag
Sanofi
70 posts
One leadership change, several major catalysts: What Vir Biotechnology must prove next
Vir Biotechnology’s finance leadership change comes as the biotechnology company manages more than $1 billion of financial resources, an important Astellas Pharma alliance and several potentially valuation-shaping clinical milestones.
Scribe Therapeutics IPO raises $128.7m as CRISPR biotech prepares to trade as SCTX
Scribe Therapeutics expanded the offering by 20% and priced shares at the top of its range, strengthening its balance sheet before crucial STX-1150 human data expected in 2027.
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
AbbVie weighs $10.9bn Apogee deal to strengthen its next immunology growth cycle
AbbVie may pay $10.9 billion for Apogee Therapeutics before Phase 3. Read what the reported deal could mean for immunology growth and ABBV stock.
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
Sanofi (SNY) wins a pivotal Tzield label expansion into recently diagnosed stage 3 type 1 diabetes
Sanofi (SNY) wins FDA accelerated approval for Tzield in recently diagnosed stage 3 type 1 diabetes, expanding its market beyond screening. Full analysis here.
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Gujarat Themis Biosyn (GUJTHEM) bets on global branded generics with €158m Sanofi portfolio deal
Find out how Gujarat Themis Biosyn’s €158m Sanofi portfolio deal could reshape its global anti-infective growth strategy.
What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy.
EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration
Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story.